S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
Log in

Marinus Pharmaceuticals News Headlines (NASDAQ:MRNS)

$2.07
-0.07 (-3.27 %)
(As of 01/27/2020 04:00 PM ET)
Today's Range
$2.02
Now: $2.07
$2.13
50-Day Range
$1.27
MA: $2.01
$2.51
52-Week Range
$0.77
Now: $2.07
$5.40
Volume735,713 shs
Average Volume1.16 million shs
Market Capitalization$111.51 million
P/E RatioN/A
Dividend YieldN/A
Beta3.12

Headlines

Marinus Pharmaceuticals (NASDAQ MRNS) News Headlines

Source:
DateHeadline
Short Interest in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Grows By 29.6%Short Interest in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Grows By 29.6%
www.americanbankingnews.com - January 27 at 12:30 PM
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Receives Average Rating of "Buy" from BrokeragesMarinus Pharmaceuticals Inc (NASDAQ:MRNS) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 23 at 3:56 AM
3 Top-Notch “Strong Buy” Stocks Under $33 Top-Notch “Strong Buy” Stocks Under $3
finance.yahoo.com - January 20 at 7:39 AM
-$0.20 Earnings Per Share Expected for Marinus Pharmaceuticals Inc (NASDAQ:MRNS) This Quarter-$0.20 Earnings Per Share Expected for Marinus Pharmaceuticals Inc (NASDAQ:MRNS) This Quarter
www.americanbankingnews.com - January 17 at 10:39 AM
Marinus Provides Business Outlook for 2020Marinus Provides Business Outlook for 2020
finance.yahoo.com - January 13 at 1:57 PM
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Sees Significant Growth in Short InterestMarinus Pharmaceuticals Inc (NASDAQ:MRNS) Sees Significant Growth in Short Interest
www.americanbankingnews.com - January 12 at 4:10 PM
Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by HC WainwrightMarinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - January 10 at 11:19 AM
Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare ConferenceMarinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference
finance.yahoo.com - January 7 at 4:44 PM
Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7%
finance.yahoo.com - December 26 at 1:20 PM
Were Hedge Funds Right Selling Marinus Pharmaceuticals Inc (MRNS)?Were Hedge Funds Right Selling Marinus Pharmaceuticals Inc (MRNS)?
finance.yahoo.com - December 24 at 2:38 PM
RAD, CAMP, ABEO and MRNS in midday moversRAD, CAMP, ABEO and MRNS in midday movers
seekingalpha.com - December 20 at 1:26 PM
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - December 14 at 1:57 AM
Marinus prices stock offering at $1.25; shares up 33%Marinus prices stock offering at $1.25; shares up 33%
seekingalpha.com - December 11 at 2:03 PM
Marinus Pharma initiates equity offering; shares down 7% after hoursMarinus Pharma initiates equity offering; shares down 7% after hours
seekingalpha.com - December 10 at 6:34 PM
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private PlacementMarinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
finance.yahoo.com - December 10 at 6:34 PM
Marinus updates on ganaxolone in epilepsyMarinus updates on ganaxolone in epilepsy
seekingalpha.com - December 9 at 1:17 PM
Marinus reports ganaxolone orphan epilepsy program updateMarinus reports ganaxolone orphan epilepsy program update
seekingalpha.com - December 9 at 8:17 AM
Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis ComplexMarinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex
finance.yahoo.com - December 9 at 8:17 AM
Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual MeetingMarinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting
finance.yahoo.com - December 7 at 8:44 AM
CLVS, AUPH, ESTC and HOV among midday moversCLVS, AUPH, ESTC and HOV among midday movers
seekingalpha.com - December 5 at 1:37 PM
Marinus Pharmaceuticals, Inc. Common Stock (MRNS) Institutional HoldingsMarinus Pharmaceuticals, Inc. Common Stock (MRNS) Institutional Holdings
www.nasdaq.com - November 11 at 12:43 AM
Marinus Pharmaceuticals EPS misses by $0.02Marinus Pharmaceuticals EPS misses by $0.02
seekingalpha.com - November 6 at 7:57 AM
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial ResultsMarinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results
finance.yahoo.com - November 6 at 7:57 AM
Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical OfficerMarinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer
finance.yahoo.com - October 29 at 8:24 AM
Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society MeetingMarinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting
finance.yahoo.com - October 17 at 7:56 AM
Thinking about buying stock in Beyond Meat, Canopy Growth, Marinus Pharmaceuticals, Rite Aid, or 22nd Century Group?Thinking about buying stock in Beyond Meat, Canopy Growth, Marinus Pharmaceuticals, Rite Aid, or 22nd Century Group?
www.benzinga.com - September 26 at 4:28 PM
Marinus Shares Rip Higher On Positive Ganaxolone Midstage Data In Epileptic SeizuresMarinus Shares Rip Higher On Positive Ganaxolone Midstage Data In Epileptic Seizures
finance.yahoo.com - September 26 at 4:28 PM
Marinus Shares Rip Higher On Positive Ganaxolone Mid-stage Data In Epileptic SeizuresMarinus Shares Rip Higher On Positive Ganaxolone Mid-stage Data In Epileptic Seizures
www.benzinga.com - September 26 at 11:23 AM
Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus TrialMarinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
finance.yahoo.com - September 26 at 9:17 AM
Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?
finance.yahoo.com - September 25 at 5:16 PM
Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth?Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth?
finance.yahoo.com - September 20 at 2:20 PM
Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock?Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock?
finance.yahoo.com - August 23 at 10:11 AM
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial ResultsMarinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results
finance.yahoo.com - August 8 at 9:53 AM
Heres Why Marinus Pharmaceuticals Stock Is Collapsing TodayHere's Why Marinus Pharmaceuticals Stock Is Collapsing Today
www.fool.com - July 24 at 10:24 AM
Marinus: Ganaxolone, Again, Proves No Better Than PlaceboMarinus: Ganaxolone, Again, Proves No Better Than Placebo
seekingalpha.com - July 24 at 10:24 AM
Marinus Sinks To 2-Year Low As Postpartum Depression Drug Found Ineffective At 28 DaysMarinus Sinks To 2-Year Low As Postpartum Depression Drug Found Ineffective At 28 Days
finance.yahoo.com - July 24 at 10:24 AM
Here's Why Marinus Pharmaceuticals Stock Is Collapsing TodayHere's Why Marinus Pharmaceuticals Stock Is Collapsing Today
finance.yahoo.com - July 24 at 10:24 AM
Marinus down 68% premarket on disappointing ganaxolone dataMarinus down 68% premarket on disappointing ganaxolone data
seekingalpha.com - July 23 at 9:25 AM
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum DepressionMarinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
finance.yahoo.com - July 23 at 9:25 AM
Is Marinus Pharmaceuticals Inc (MRNS) A Good Stock To Buy?Is Marinus Pharmaceuticals Inc (MRNS) A Good Stock To Buy?
finance.yahoo.com - June 30 at 8:26 AM
Announcing: Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Increased An Energizing 187% In The Last Three YearsAnnouncing: Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Increased An Energizing 187% In The Last Three Years
finance.yahoo.com - June 20 at 7:38 PM
Marinus Pharmaceuticals to Participate at Upcoming Investor ConferencesMarinus Pharmaceuticals to Participate at Upcoming Investor Conferences
finance.yahoo.com - June 3 at 8:26 AM
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial ResultsMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
www.nasdaq.com - May 1 at 8:26 AM
How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own?How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own?
finance.yahoo.com - April 26 at 6:50 PM
Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock OptionsImplied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
finance.yahoo.com - March 19 at 7:34 PM
Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results - GlobeNewswireMarinus Pharmaceuticals Provides Business Update and 2018 Financial Results - GlobeNewswire
www.globenewswire.com - March 11 at 7:33 PM
Marinus Pharmaceuticals Provides Business Update and 2018 Financial ResultsMarinus Pharmaceuticals Provides Business Update and 2018 Financial Results
finance.yahoo.com - March 11 at 8:41 AM
Andrew TsaiAndrew Tsai
www.benzinga.com - March 6 at 8:34 AM
Marinus up 11% premarket on late-stage study of ganaxolone in rare type of epilepsyMarinus up 11% premarket on late-stage study of ganaxolone in rare type of epilepsy
seekingalpha.com - March 6 at 8:34 AM
Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related EpilepsyMarinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
finance.yahoo.com - March 6 at 8:34 AM
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel